Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01 Clinical Trial Not Allowed)
Grant provides access to high-throughput genotyping and sequencing resources for identifying genes contributing to human health and disease, and enhancing biorepositories with genotype or next-gen data. Managed by NHGRI and available via CIDR.
Funder: National Institutes of Health
Due Dates: Continuous receipt (applications accepted at any time) | Expires July 9, 2026
Funding Amounts: No direct funds; provides access to high-throughput sequencing/genotyping services (X01 mechanism, up to 5 years)
Summary: Provides access to advanced genotyping, sequencing, and statistical genetics services for research on genes and genetic modifications relevant to human health and disease.
Key Information: No monetary award; applicants must have or obtain permission from a participating NIH institute and cover ancillary costs from other sources.
Description
This NIH-wide initiative, managed by the National Human Genome Research Institute (NHGRI), offers access to the Center for Inherited Disease Research (CIDR) for high-throughput genotyping, sequencing, and supporting statistical genetics services. The program is designed to support research that identifies genes or genetic modifications contributing to human health and disease, or to enhance existing biorepositories by adding genotype or next-generation sequence data. CIDR specializes in genomic services that are not efficiently performed in individual investigator laboratories, providing state-of-the-art platforms and expert support.
Key research areas include:
- Gene discovery projects with strong evidence for genetic or epigenetic factors affecting traits
- Large-scale genotyping or sequencing of well-phenotyped human sample collections
- Projects adding genomic data to existing collections for further characterization or stratification
- Human genome-wide association studies (GWAS), whole-genome/exome/custom sequencing, high-throughput SNP genotyping, and DNA methylation analyses
Applicants are expected to share generated data broadly with the scientific community, and projects with rich, shareable clinical and phenotypic data are prioritized.
